|
1
|
Carethers JM and Stoffel EM: Lynch
syndrome and Lynch syndrome mimics: The growing complex landscape
of hereditary colon cancer. World J Gastroenterol. 21:9253–9261.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de la Chapelle A: The incidence of Lynch
syndrome. Fam Cancer. 4:233–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sijmons RH and Hofstra RM: Review:
Clinical aspects of hereditary DNA Mismatch repair gene mutations.
DNA Repair (Amst). 38:155–162. 2016. View Article : Google Scholar
|
|
4
|
Thompson BA, Spurdle AB, Plazzer JP,
Greenblatt MS, Akagi K, Al-Mulla F, Bapat B, Bernstein I, Capellá
G, den Dunnen JT, et al InSiGHT: Application of a 5-tiered scheme
for standardized classification of 2,360 unique mismatch repair
gene variants in the InSiGHT locus-specific database. Nat Genet.
46:107–115. 2014. View
Article : Google Scholar
|
|
5
|
Peltomäki P: Role of DNA mismatch repair
defects in the pathogenesis of human cancer. J Clin Oncol.
21:1174–1179. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miyaki M, Konishi M, Tanaka K,
Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M
and Mori T: Germline mutation of MSH6 as the cause of hereditary
nonpolyposis colorectal cancer. Nat Genet. 17:271–272. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berends MJ, Wu Y, Sijmons RH, Mensink RG,
van der Sluis T, Hordijk-Hos JM, de Vries EG, Hollema H, Karrenbeld
A, Buys CH, et al: Molecular and clinical characteristics of MSH6
variants: An analysis of 25 index carriers of a germline variant.
Am J Hum Genet. 70:26–37. 2002. View
Article : Google Scholar
|
|
8
|
Nilbert M, Wikman FP, Hansen TV, Krarup
HB, Orntoft TF, Nielsen FC, Sunde L, Gerdes AM, Cruger D, Timshel
S, et al: Major contribution from recurrent alterations and MSH6
mutations in the Danish Lynch syndrome population. Fam Cancer.
8:75–83. 2009. View Article : Google Scholar
|
|
9
|
Senter L, Clendenning M, Sotamaa K, Hampel
H, Green J, Potter JD, Lindblom A, Lagerstedt K, Thibodeau SN,
Lindor NM, et al: The clinical phenotype of Lynch syndrome due to
germ-line PMS2 mutations. Gastroenterology. 135:419–428. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Niessen RC, Hofstra RM, Westers H,
Ligtenberg MJ, Kooi K, Jager PO, de Groote ML, Dijkhuizen T,
Olderode-Berends MJ, Hollema H, et al: Germline hypermethylation of
MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome.
Genes Chromosomes Cancer. 48:737–744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goel A, Nguyen TP, Leung HC, Nagasaka T,
Rhees J, Hotchkiss E, Arnold M, Banerji P, Koi M, Kwok CT, et al:
De novo constitutional MLH1 epimutations confer early-onset
colorectal cancer in two new sporadic Lynch syndrome cases, with
derivation of the epimutation on the paternal allele in one. Int J
Cancer. 128:869–878. 2011. View Article : Google Scholar
|
|
12
|
Kuiper RP, Vissers LE, Venkatachalam R,
Bodmer D, Hoenselaar E, Goossens M, Haufe A, Kamping E, Niessen RC,
Hogervorst FB, et al: Recurrence and variability of germline EPCAM
deletions in Lynch syndrome. Hum Mutat. 32:407–414. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nyström-Lahti M, Kristo P, Nicolaides NC,
Chang SY, Aaltonen LA, Moisio AL, Järvinen HJ, Mecklin JP, Kinzler
KW, Vogelstein B, et al: Founding mutations and Alu-mediated
recombination in hereditary colon cancer. Nat Med. 1:1203–1206.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grindedal EM, Aarset H, Bjørnevoll I,
Røyset E, Mæhle L, Stormorken A, Heramb C, Medvik H, Møller P and
Sjursen W: The Norwegian PMS2 founder mutation c.989-1G > T
shows high penetrance of microsatellite instable cancers with
normal immunohistochemistry. Hered Cancer Clin Pract. 12:122014.
View Article : Google Scholar
|
|
15
|
Foulkes WD, Thiffault I, Gruber SB,
Horwitz M, Hamel N, Lee C, Shia J, Markowitz A, Figer A, Friedman
E, et al: The founder mutation MSH2*1906G→C is an important cause
of hereditary nonpolyposis colorectal cancer in the Ashkenazi
Jewish population. Am J Hum Genet. 71:1395–1412. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun S, Greenwood CM, Thiffault I, Hamel N,
Chong G and Foulkes WD: The HNPCC associated MSH2*1906G→C founder
mutation probably originated between 1440 CE and 1715 CE in the
Ashkenazi Jewish population. J Med Genet. 42:766–768. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goldberg Y, Porat RM, Kedar I, Shochat C,
Galinsky D, Hamburger T, Hubert A, Strul H, Kariiv R, Ben-Avi L, et
al: An Ashkenazi founder mutation in the MSH6 gene leading to
HNPCC. Fam Cancer. 9:141–150. 2010. View Article : Google Scholar
|
|
18
|
Raskin L, Schwenter F, Freytsis M,
Tischkowitz M, Wong N, Chong G, Narod SA, Levine DA, Bogomolniy F,
Aronson M, et al: Characterization of two Ashkenazi Jewish founder
mutations in MSH6 gene causing Lynch syndrome. Clin Genet.
79:512–522. 2011. View Article : Google Scholar
|
|
19
|
Tiwari AK, Roy HK and Lynch HT: Lynch
syndrome in the 21st century: Clinical perspectives. QJM.
109:151–158. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hendriks YM, Wagner A, Morreau H, Menko F,
Stormorken A, Quehenberger F, Sandkuijl L, Møller P, Genuardi M,
Van Houwelingen H, et al: Cancer risk in hereditary nonpolyposis
colorectal cancer due to MSH6 mutations: Impact on counseling and
surveillance. Gastroenterology. 127:17–25. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Plaschke J, Engel C, Krüger S,
Holinski-Feder E, Pagenstecher C, Mangold E, Moeslein G, Schulmann
K, Gebert J, von Knebel Doeberitz M, et al: Lower incidence of
colorectal cancer and later age of disease onset in 27 families
with pathogenic MSH6 germline mutations compared with families with
MLH1 or MSH2 mutations: The German Hereditary Nonpolyposis
Colorectal Cancer Consortium. J Clin Oncol. 22:4486–4494. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
ten Broeke SW, Brohet RM, Tops CM, van der
Klift HM, Velthuizen ME, Bernstein I, Capellá Munar G, Gomez Garcia
E, Hoogerbrugge N, Letteboer TG, et al: Lynch syndrome caused by
germline PMS2 mutations: Delineating the cancer risk. J Clin Oncol.
33:319–325. 2015. View Article : Google Scholar
|
|
23
|
Stoffel E, Mukherjee B, Raymond VM, Tayob
N, Kastrinos F, Sparr J, Wang F, Bandipalliam P, Syngal S and
Gruber SB: Calculation of risk of colorectal and endometrial cancer
among patients with Lynch syndrome. Gastroenterology.
137:1621–1627. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moreira L, Balaguer F, Lindor N, de la
Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L,
Gallinger S, Newcomb PA, et al EPICOLON Consortium: Identification
of Lynch syndrome among patients with colorectal cancer. JAMA.
308:1555–1565. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
den Dunnen JT and Antonarakis SE: Mutation
nomenclature. Curr Protoc Hum genet. 37:7.13.1–7.13.8. 2003.
View Article : Google Scholar
|
|
26
|
Lagerstedt Robinson K, Liu T, Vandrovcova
J, Halvarsson B, Clendenning M, Frebourg T, Papadopoulos N, Kinzler
KW, Vogelstein B, Peltomäki P, et al: Lynch syndrome (hereditary
nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst.
99:291–299. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cederquist K, Emanuelsson M, Göransson I,
Holinski-Feder E, Müller-Koch Y, Golovleva I and Grönberg H:
Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with
double primary cancers of the colorectum and the endometrium: A
population-based study in northern Sweden. Int J Cancer.
109:370–376. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Charbonnier F, Olschwang S, Wang Q,
Boisson C, Martin C, Buisine MP, Puisieux A and Frebourg T: MSH2 in
contrast to MLH1 and MSH6 is frequently inactivated by exonic and
promoter rearrangements in hereditary nonpolyposis colorectal
cancer. Cancer Res. 62:848–853. 2002.PubMed/NCBI
|
|
29
|
Smith MJ, Urquhart JE, Harkness EF, Miles
EK, Bowers NL, Byers HJ, Bulman M, Gokhale C, Wallace AJ, Newman
WG, et al: The contribution of whole gene deletions and large
rearrangements to the mutation spectrum in inherited tumor
predisposing syndromes. Hum Mutat. 37:250–256. 2016. View Article : Google Scholar
|
|
30
|
Clendenning M, Baze ME, Sun S, Walsh K,
Liyanarachchi S, Fix D, Schunemann V, Comeras I, Deacon M, Lynch
JF, et al: Origins and prevalence of the American founder mutation
of MSH2. Cancer Res. 68:2145–2153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tomsic J, Liyanarachchi S, Hampel H, Morak
M, Thomas BC, Raymond VM, Chittenden A, Schackert HK, Gruber SB,
Syngal S, et al: An American founder mutation in MLH1. Int J
Cancer. 130:2088–2095. 2012. View Article : Google Scholar :
|
|
32
|
Snowsill T, Huxley N, Hoyle M,
Jones-Hughes T, Coelho H, Cooper C, Frayling I and Hyde C: A
systematic review and economic evaluation of diagnostic strategies
for Lynch syndrome. Health Technol Assess. 18:1–406. 2014.
View Article : Google Scholar : PubMed/NCBI
|
